Compare Davita Inc (DVA) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs The Coca-Cola Co K — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while The Coca-Cola Co K trades at $83.18 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 24× Davita Inc's market cap, and The Coca-Cola Co K pays a 2.55% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | KO | |
|---|---|---|
Market Cap | $14.92B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $235.71 | $84.25 |
52-Week Low | $103.87 | $65.67 |
Enterprise Value | $27.47B | $387.52B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 27.8% net margin and 45.8% ROE, though valuation multiples like P/E of 26.5 appear elevated. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
The outlook remains positive with a $89.75 analyst target suggesting 6.5% upside, supported by dividend reliability. Key risks include high debt levels and regional demand volatility. The stock presents a steady growth opportunity with moderate upside potential balanced by valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
